Antibodies are proteins that people's bodies make to fight viruses, such as the virus that causes COVID-19. Antibodies made in a laboratory act like natural antibodies to limit the amount of virus in your body. Laboratory and synthetically produced antibodies are called monoclonal antibodies.
Research studies have shown that infusion of monoclonal antibodies in the early stages of COVID-19 infection can decrease the chance that people with risk factors for severe disease will get worse, and decrease the chance that they would need to return to the Emergency Department, or be admitted to the hospital for COVID-19 symptoms.
Monoclonal antibody treatment is time-sensitive, and must be given soon after a COVID-19 diagnosis is made. It is most effective when given early, and cannot be given if symptoms have been present for 10 days or more.
If you were seen at Community Hospital’s Emergency department, staff will contact you by phone if you are eligible. You may also reply through MyChart messaging if you are interested, and someone will contact you by phone with next steps to schedule an infusion appointment. If you received a positive test and think you are eligible, please contact your local doctor so that they can determine your eligibility for treatment.
Treatment could take as little as 2 hours or less, but can vary due to other factors.
Being fully vaccinated against COVID-19 is not an absolute contraindication to treatment, but there is no evidence to support benefit of monoclonal antibody treatment for breakthrough infection in someone with pre-existing vaccine-induced immunity. Consideration may be given to treating a fully vaccinated person if there is evidence of suboptimal response to vaccination such as a negative COVID-19 serology or an immunosuppressed state that would have precluded development of an adequate vaccine response (e.g. prior treatment with rituximab).
There is limited experience using REGEN-COV (casirivimab and imdevimab) and Sotrovimab in pregnant women or breastfeeding mothers. For a mother and unborn baby, the benefit of receiving REGEN-COV (casirivimab and imdevimab) and Sotrovimab may be greater than the risk of using the product. If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.
Monoclonal antibody infusions have not received full FDA review and approval and, like all other medications, come with some risk. See below for more information on monoclonal antibody infusions: